{"id":63462,"date":"2026-04-17T22:11:34","date_gmt":"2026-04-17T14:11:34","guid":{"rendered":"https:\/\/flcube.com\/?p=63462"},"modified":"2026-04-17T22:11:35","modified_gmt":"2026-04-17T14:11:35","slug":"annoroad-gene-technology-files-for-hong-kong-ipo-to-capitalize-on-integrated-molecular-diagnostics-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63462","title":{"rendered":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform"},"content":{"rendered":"\n<p><strong>Annoroad Gene Technology (Beijing) Co., Ltd.<\/strong>, a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the <strong>Hong Kong Stock Exchange<\/strong> for an <strong>initial public offering (IPO)<\/strong>. The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-model-amp-core-offerings\">Business Model &amp; Core Offerings<\/h2>\n\n\n\n<p>Annoroad operates at the intersection of <strong>in vitro diagnostics (IVD)<\/strong> and <strong>multi-omics research services<\/strong>, offering a vertically integrated suite of products and services:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IVD Detection Kits:<\/strong> In-house developed, <strong>gene sequencing-based<\/strong> diagnostic kits, including:<\/li>\n\n\n\n<li><strong>NIPT kits<\/strong> for fetal genetic abnormality detection (Class III certificate, 2017).<\/li>\n\n\n\n<li><strong>CNV-seq kits<\/strong> for copy number variation analysis (Class III certificate, 2024).<\/li>\n\n\n\n<li><strong>Instrumentation:<\/strong> Proprietary <strong>gene sequencers<\/strong>.<\/li>\n\n\n\n<li><strong>Software:<\/strong> Integrated <strong>bioinformatics analysis software<\/strong>.<\/li>\n\n\n\n<li><strong>Services:<\/strong> Comprehensive <strong>technical support<\/strong> and <strong>laboratory design services<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p>This end-to-end model allows Annoroad to provide seamless solutions from sample to insight, differentiating it from competitors who may offer only fragmented components.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones-amp-market-position\">Regulatory Milestones &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2017:<\/strong> Became one of the <strong>first companies in China<\/strong> to receive a <strong>Class III medical device certificate<\/strong> for its NIPT kit, the highest regulatory classification for IVDs in China, signifying high risk and stringent review.<\/li>\n\n\n\n<li><strong>2024:<\/strong> Secured another <strong>Class III certificate<\/strong> for its CNV-seq kit, further solidifying its position as a regulatory leader in advanced genomic diagnostics.<\/li>\n<\/ul>\n\n\n\n<p>The Hong Kong IPO is poised to provide Annoroad with significant capital to accelerate R&amp;D, expand its commercial footprint across Asia, and potentially pursue strategic acquisitions to broaden its multi-omics capabilities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<p>The move comes amid strong global demand for precision medicine and genomic testing. By listing in Hong Kong, Annoroad gains access to international capital while maintaining its primary focus on the vast and growing Chinese healthcare market. Its established track record of securing top-tier regulatory approvals de-risks its technology platform for investors.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Annoroad\u2019s proposed IPO and future business plans. The completion of the offering is subject to market conditions and regulatory approvals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63463,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3954,72],"class_list":["post-63462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-annoroad-gene-technology","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO). The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63462\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform\" \/>\n<meta property=\"og:description\" content=\"Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO). The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63462\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T14:11:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-17T14:11:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform\",\"datePublished\":\"2026-04-17T14:11:34+00:00\",\"dateModified\":\"2026-04-17T14:11:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1704.webp\",\"keywords\":[\"Annoroad Gene Technology\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63462#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63462\",\"name\":\"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1704.webp\",\"datePublished\":\"2026-04-17T14:11:34+00:00\",\"dateModified\":\"2026-04-17T14:11:35+00:00\",\"description\":\"Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO). The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63462\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1704.webp\",\"width\":1080,\"height\":608,\"caption\":\"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63462#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO). The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63462","og_locale":"en_US","og_type":"article","og_title":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform","og_description":"Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO). The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.","og_url":"https:\/\/flcube.com\/?p=63462","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-17T14:11:34+00:00","article_modified_time":"2026-04-17T14:11:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63462#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63462"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform","datePublished":"2026-04-17T14:11:34+00:00","dateModified":"2026-04-17T14:11:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63462"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63462#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp","keywords":["Annoroad Gene Technology","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63462#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63462","url":"https:\/\/flcube.com\/?p=63462","name":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63462#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63462#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp","datePublished":"2026-04-17T14:11:34+00:00","dateModified":"2026-04-17T14:11:35+00:00","description":"Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing solutions, has filed a prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO). The company is focused on advancing both clinical diagnostics and life science research through its proprietary molecular diagnostics platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63462#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63462"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63462#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp","width":1080,"height":608,"caption":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63462#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1704.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63462"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63462\/revisions"}],"predecessor-version":[{"id":63464,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63462\/revisions\/63464"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63463"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}